Merck & Co Inc

NYSE:MRK  
79.97
-0.78 (-0.97%)
5:12:18 PM EDT: $79.96 -0.01 (-0.01%)
Products

Merck And Ridgeback’S Molnupiravir Receives U.S. FDA Emergency Use Authorization For The Treatment Of High-Risk Adults With Mild To Moderate Covid-19

Published: 12/23/2021 16:16 GMT
Merck & Co Inc (MRK) - Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-risk Adults With Mild to Moderate Covid-19.
Merck & Co Inc - Anticipates That It Will Begin Shipping Molnupiravir to Amerisourcebergen, Sole Distributor of Molnupiravir, Within Days.
Merck & Co Inc - Authorization is Based on Phase 3 Move-out Trial.